Authors:
Marc-Robin Gruener
1
;
Jessica Helbling
2
;
Hyungmin Koh
2
;
Victoire Stalder
2
and
Tobias Kowatsch
3
;
1
;
4
Affiliations:
1
School of Medicine, University of St. Gallen, St. Gallen, Switzerland
;
2
University of St. Gallen, St. Gallen, Switzerland
;
3
Institute for Implementation Science in Health Care, University of Zurich, Zurich, Switzerland
;
4
Centre for Digital Health Interventions, Department of Management, Technology, and Economics at ETH Zurich, Zurich, Switzerland
Keyword(s):
Business Models, Digital Health Companies, Funding, Healthcare, Scalability, Type 1 Diabetes.
Abstract:
This paper aims to assess how the top-funded digital health companies in T1DM can create value for customers and which implications this has in terms of scalability. Med tech companies, academia, and policymakers should be able to make better strategic decisions based on the findings provided. Companies were identified using a leading venture capital database, PitchBook. Our analysis revealed that 50% of the thirty top-funded companies pursue a Layer Player strategy to generate value for T1DM patients. We recommend that companies in T1DM focus more on automated services such as conversational agents to improve scalability. In terms of scalability, many companies have room for improvement by increasingly relying on automated services, among other things.